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Background: Leukemia, a heterogeneous clonal disorder of hematopoietic progenitor cells, presents a world-wide
health problem, especially in childhood. F1F0 ATPase, an inner mitochondrial enzyme, is expressed on the plasma
membrane of tumor cells, and its inhibition induces both anti-angiogenic and anti-tumorigenic activity.
Methods: Monoclonal Antibody (McAb) against ATPase was produced by polyethylene glycol-mediated fusions
and screened by ELISA. Proliferation, cell cycle and apoptosis of cells were analyzed when the surface ATPase of
cells was blockaded with McAb.
Results: We detected cell-membrane expression of the F1F0 ATPase β subunit on 0.1% to 56% of the 11 cell lines
derived from leukemia, including acute myeloid leukemia (AML). We produced a monoclonal antibody, McAb7E10,
which recognizes both the native and recombinant ATPase β subunit, with a dissociation constant (KD) of 3.26E–10.
We demonstrate that McAb7E10 binds to ATPase at the cell surface, where it is able to inhibit ATP synthesis.
McAb7E10 significantly inhibited proliferation of AML cell lines in vitro: the relative inhibitory rates of 50 μg/mL
McAb7E10 treated MV4-11and HL-60 cells were 69.6% and 81.9% respectively. Cell cycle analysis indicated that
McAb7E10 significantly induced apoptosis in MV4-11 and HL-60 cells: the relative rates of apoptosis in 5, 10 and
50ug/mL McAb7E10 treated MV4-11 cells was 3.6 ± 0.83%, 8.4 ± 1.69% and 17.3 ± 2.56% compared to 1.5% ± 0.85%
in mouse IgG treated cells (p < 0.01). The relative rate of apoptosis in 5, 10 and 50ug/mL McAb7E10 treated HL-60
cells was 5.5 ± 2.37%, 11.3 ± 3.62% and 19.9 ± 3.31% compared to 1.56% ± 0.97% in mouse IgG treated cells
(p < 0.01). Annexin V staining demonstrated that the relative apoptotic rates in 50 μg/mL McAb7E10 treated MV4-11
and HL-60 cells were 50.5% ± 7.04% and 32.9% ± 4.52%, respectively, significantly higher than IgG control antibody
treated cells were 21.9% ± 3.11% and 15.3% ± 3.95%, p < 0.01.
Conclusions: These findings indicate that ectopic expression of ATPase β subunit may be a tumor-associated
antigen in hematological malignancies. The F1F0 ATPase β subunit provides a potential target for immunotherapy
in AML and hematological malignancies.
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F1F0 ATP synthase is a complex molecular motor re-
sponsible for the majority of ATP synthesis in all organ-
isms [1,2]. The ATP synthase β subunit is mostly
expressed in the inner mitochondrial membrane of nor-
mal cells [3-9]. Over the last few years, reports by sev-
eral independent groups have described the presence of
various subunits of ATP synthase at the cell surface of
mammalian cells, which have been termed ecto-F1F0-
ATPase [5,10-13]. Recent studies have shown that the β-
subunits of F1F0 ATPase are located on the plasma
membrane, as well as within the mitochondrial mem-
brane of human vascular endothelial cells and tumor
cells [5,6,10,14]. Most of the cell lines which are
reported to express ecto-F1F0-ATPase β-subunits are
leukemia cell lines, including K562, Raji [15], Daudi,
U937 [11], Jurkat [16], ST-Emo and Rma-S [17].
In endothelial cells, the ecto-F1F0-ATPase β subunit has
been identified as a receptor for angiostatin, a naturally oc-
curring inhibitor of angiogenesis [5,14] which inhibits
endothelial cell proliferation, tube formation and migration.
Several conflicting reports have debated whether ecto-
F1F0-ATPase is functional in tumor cells [3,10,15,17-20].
Recent data has shown that the mitochondrial F1-
ATPase is expressed on tumor cell surface and promotes
tumor recognition by Vgamma9Vdelta2 T cells. [11]. T
lymphocytes are known to participate in the immune re-
sponse against various intracellular pathogens, including
tumor cells. Additionally, other research has demon-
strated that inhibition of the ecto-F1F0-ATPase β-
subunit is directly cytotoxic to tumor cells [3,18,21]. This
data indicates that identification of novel ecto-F1F0-
ATPase β subunit inhibitors, with both anti-angiogenic
and anti-tumorigenic activities, may confer a greater
therapeutic advantage by affecting cancer cells via by
multiple mechanisms with potentially additive effects.
In this study, we analyzed expression of the ecto-F1F0-
ATPase β subunit in eleven cell lines derived from
hematological malignancies and HUVECs, a positive control
human vascular endothelial cell line. Most of cell lines
derived from hematological malignancies expressed the
ecto-F1F0-ATPase β subunit. We produced a monoclonal
antibody 7E10 (McAb7E10) specific to the human F1F0
ATPase β subunit, which inhibited proliferation and induced
significant apoptosis in the acute myeloid leukemia (AML)
cell lines, MV4-11 and HL-60. These results suggest that the
abnormal cell surface expression of the ecto-F1F0-ATPase β
subunit may provide a potential target for cancer immuno-
therapy in hematological malignancies, particularly AML.
Methods
Cell culture
Cell lines derived from hematological malignancies (HL-
60, MV4-11, U937, K562, Raji, and Jurkat) were obtainedfrom the American Type Culture Collection (ATCC).
SHI-1, MOLT4, DAMI, CCRF and 697 cell lines (gifts
from Professor Wang Jian-Rong, The Cyrus Tang
Hematology center of Soochow University). The entire
cell lines were maintained at 37°C in the RPMI 1640
supplemented with 10% fetal bovine serum, 100 U/ml
penicillin and 100 mg/ml streptomycin [22]. HUVEC
cells were a gift from Professor Yang Zhi-Hua (Depart-
ment of Cell and Molecular Biology, Cancer Institute,
Chinese Academy of Medical Sciences, Beijing, China)
and were cultured in M200 basal culture media supple-
mented with low serum growth supplement (Cascade
Biologics, PL, USA), 100 U/ml penicillin and 100 mg/ml
streptomycin [23-25]. All cells were cultured at 37°C in
a 5% CO2 humidified atmosphere.Flow cytometric assay
Cells were collected, washed twice with phosphate buf-
fered saline (PBS), adjusted to 1 × 106 cells/ml, and incu-
bated with ATP synthase subunit beta monoclonal
antibody (1:300; MitoScience MS503, EA, USA) for
30 min at 4°C. After washing three times with PBS,
fluorescein-isothiocyanate (FITC)-labeled goat anti-
mouse IgG (Jackson,WG, PA) diluted in PBS was added,
incubated for 20 min at 4°C, then cells were washed
three times with PBS, 1 ug/ml PI(Propidium Iodide,
Sigma, St. Louis, MO, USA)) was added to exclude the
dead cells and membrane antigen expression was ana-
lyzed using a fluorescence-activated cell sorter (ESP
Elite, Beckman Coulter, Fullerton, CA, USA). All experi-
ments were performed three times.Production of functional F1F0 ATPase β subunit antibody
Six to eight weeks old female BALB/c mice were sub-
cutaneously immunized with hATP5B (F1F0 ATPase β
subunit) which had been expressed using a prokaryotic
system, as previously described [3], and mixed with
Freund’s complete adjuvant (Sigma, St. Louis, MO,
USA). The antibody valences in peripheral blood were
determined using an ELISA as Gou, L. T. described [21],
and three days after the last boost, 5 × 108 sensitized
spleen cells were harvested, mixed and fused with 1 ×
108 SP2/0 myeloma cells, in 50% polyethylene glycol
1500 in a proportion of 8:1. The fused cells were plated
in 96-well plates (6 × 105/well) and cultured for two
weeks in RPMI 1640 with 10% fetal calf serum contain-
ing hypoxanthine, aminopterin, and thymidine to select
for positive hybrid cells. The positive hybridoma cells
were subcloned by limiting dilution, and 10–12 week old
female BALB/c mice were inoculated with 3 × 106 hybri-
doma cells [3,26]. The antibodies were further purified
from the ascites via Protein-A affinity chromatography
[3]. The antibody with the highest valence against the
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used in further experiments.
Western blotting and BIAcore analysis
Cellular proteins were extracted in 40 mM Tris–HCl
(pH 7.4) containing 150 mM NaCl and 1% (v/v) Triton
X-100 and supplemented with a cocktail of protease
inhibitors. Equal amounts of protein were resolved on
12% SDS-PAGE gels then transferred to a PVDF mem-
brane. After blocking with 5% non-fat milk, the mem-
branes were incubated with McAb7E10 antibody
overnight at 4°C, then with HRP-conjugated sheep anti-
mouse IgG secondary antibody (Vector, Burlingame, CA,
USA). After washing, the protein bands were visualized
using the SuperEnhanced chemiluminescence detection
kit (Applygen Technologies Inc., Beijing, China) and X-
ray film (Kodak,NY,USA). The binding and dissociation
kinetics of McAb7E10 with the recombinant ATPase β
subunit were determined using a BIAcore surface
plasmon resonance instrument (Pharmacia, Uppsala,
Sweden) [27-31]. Briefly, 1400 RU of the recombinant
ATPase β subunit (25 ug/mL in 10 mmol/L sodium acet-
ate, pH 4.5) were covalently bound through amino
groups to a CM5 sensor chip [32-34].
ATPase activity assay
1*104 cells per well were equilibrated with serum-free
medium at 37°C with 5% CO2 overnight, respectively, in
96-well plates. Then the cells were treated with different
concentrations of McAb7E10, oligomycin (Sigma, St.
Louis, MO, USA), a known inhibitor of ATPase F1 or
mouse IgG for 30 min. The cells were then incubated
with adenosine diphosphate (Sigma, St. Louis, MO,
USA) for 60 s, and supernatants were removed and
assayed for ATP production using a bioluminescence
assay kit (Invitrogen, Carlsbad, CA, USA). Samples were
injected with the ATP assay mixture (Promega, Madison,
WI, USA) and incubated for 10 min to stabilize the lu-
minescence signal. Recordings were made in an Analyst
HT (Molecular Devices, Sunnyvale, CA, USA) over a
20 s period. Data are expressed as moles of ATP per well
based on standards determined under the same condi-
tions during each experiment.
Cell proliferation assay
Acute myeloid leukemia (AML) cells (MV4-11 and HL-
60) were seeded in 96-well plates at 50,000 cells per well
and 5–50 ug/mL mouse control IgG or 5–50 ug/mL
McAb7E10 antibody was added. After 24, 48, 72, 96 or
120 h, 20 μL 5 mg/ml MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5- diphenyltetrazolium bromide) solution was
added to each well, incubated at 37°C for 4 h, then the
media was removed and 200 μL dimethylsulfoxide
(DMSO) was added. Optical density (OD) values weremeasured at 490 nm using a scanning multi-well spec-
trophotometer (BioRad Model 550, Hercules, CA, USA),
and the survival rates of McAb7E10 treated cells were
calculated relative to the control antibody treated cells.
All experiments were performed in triplicate and
repeated twice. The results were analyzed using ANOVA
and the Student-Newman-Keuls tests, p < 0.05 were con-
sidered significant.
Cell cycle analysis
Cells were harvested and a single cell suspension was
prepared in buffer (PBS + 2% FBS), washed twice and
adjusted to 1 × 106 cells/ml. Aliquots of 1 ml cell sus-
pension were placed in 15 ml polypropylene V-
bottomed tubes and 3 ml cold absolute ethanol was
added to fix the cells for at least 1 h at 4°C. Cells were
washed twice in PBS, 1 ml propidium iodide staining
solution was added to the cell pellet, mixed well, and
50 μl RNAse A stock solution was added and incubated
for 3 h at 4°C before flow cytometry analysis was
performed.
Cell apoptosis analysis
Cell apoptosis was analyzed using the Annexin V-FITC
Apoptosis Detection Kit (Cat. No 556570; BD Franklin
Lakes, NJ, USA) according to the manufacturer’s
instructions. Briefly, incubated with mouse IgG or
McAb7E10 antibody for 48 hours, then cells were
washed twice with cold PBS, resuspended in 1x Binding
Buffer at 1 × 106 cells/ml and a 100 μl (1 × 105 cells) ali-
quot was transferred to a 5 ml culture tube. 5 μl
Annexin V and 10 μl vital dye was added, gently mixed,
incubated for 15 min at RT in the dark, then 400 μl of
1x Binding Buffer was added to each tube and immedi-
ately analyzed by flow cytometry. All experiments were
performed three times.
Statistical analysis
All data are presented as mean ± SD. Statistical analysis
was performed using SPSS statistical software (SPSS Inc,
Chicago, IL, USA), p ≤ 0.05 were considered significant.
Results and discussion
The ecto-ATPase β subunit is expressed in cell lines from
hematologic malignancies
The ATP synthase β subunit is known to be constitu-
tively expressed in the inner mitochondrial membrane
of normal cells, and ectopically expressed in primary
cultured endothelial cells [3-7]. Liver carcinoma cells
and lung carcinoma cells also express the ATP syn-
thase β subunit on their cell surface [18,21]. In this
study, we found that the ATP synthase β subunit is
upregulated and ectopically expressed on the cell sur-
face of human AML cells. Using flow cytometry, the β
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cell lines (two ALL cell lines 697 and Jurkat; three
lymphoma cell lines CCRF, Raji and MOLT4; six mye-
loid leukemia cell lines MV4-11, SHI-1,DAMI, K562,
HL-60 and U937). MV4-11, HL-60 and Jurkat are the
top three cells (Figure 1). The β subunit of F1F0
ATPase was also detected in the positive control
HUVEC cell line (Figure 1). The number of cells
expressing ecto-ATPase β subunit on the cell mem-
brane ranged from 0.1% to 56%. The percentage ofFigure 1 Expression of ecto-ATPase β subunit in cell lines from hema
synthase subunit β monoclonal antibody or mouse IgG control antibody, t
and membrane ATP synthase subunit β expression was analyzed using fluo
cells and HUVEC cells incubated with control IgG and ATP synthase subunicells expressing ecto-ATPase β subunit on the cell
membrane in the K562 cell line (17.2%), derived from
a 53 year old female CML patient, and the monocytic
cell line U937 (18.6%), were similar to the previous re-
port of Scotet E et al. [11].
Production and characterization of McAb7E10
In order to generate a monoclonal antibody (McAb)
against the natural epitopes of the ATPase catalytic
subunit, we immunized BALB/c mice with both naturaltological malignancies. Cells were collected, incubated with an ATP
hen with fluorescein-isothiocyanate (FITC)-labeled goat anti-mouse IgG
rescence activated cell sorting (FACS). FACS results of 11 leukemia
t β monoclonal antibody.
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had been expressed in prokaryotes. After several fusion
experiments, hundreds of monoclonal hybridoma cells
were obtained. One immunoglobulin G1 (IgG1) hybri-
doma clone, named McAb7E10, recognized both the
native and recombinant ATPase β subunit. In Western
blot analysis, the McAb7E10 antibody identified a single
band corresponding to the molecular mass of the
ATPase β subunit, and did not cross react with the
ATPase α subunit (Figure 2A). The affinity of
McAb7E10 to the recombinant ATPase β subunit was
evaluated using BIAcore, and the dissociation constant
was KDMcAb7E10 = 3.26E
–10 (Figure 2B), which is higher
than the KD of 4.24E–9 of the previously characterized
ATPase β subunit antibody McAb178-5 G10 [3].
McAb7E10 inhibits cell surface ATP generation in AML
cells
To examine the inhibitory effect of the antibody on ATP
synthesis, a cell surface ATP generation assay was per-
formed. Results showed that McAb7E10 antibody signifi-
cantly inhibited ATP synthesis in AML cells. The
relative inhibitory rates in 25, 50 and 100 ug/mL
McAb7E10 treated MV4-11 cells were 14.1%, 23.1% and
25.0%, in HL-60 cells were 16.1%, 28.1% and 29.3% re-
spectively (Figure 3A, 3B). The maximal inhibition of
McAb7E10 to MV4-11 and HL-60 cells was ~30%
(300 μg/mL), and the maximal inhibition of oligomycin
to both cells was ~80% (300 μg/mL).Figure 2 Production and characterization of McAb7E10. A monoclonal
developed and named McAb7E10. (A) In Western blot analysis, the McAb7
protein lysate (lane 1) and recombinant ATPase β subunit protein (lane 2),
(lane3). (B) The affinity of McAb7E10 to recombinant ATPase β subunit was
ATPase β subunit was evaluated using BIAcore, and the dissociation constaMcAb7E10 inhibits AML cell proliferation and induces
apoptosis in AML cells
This study provides evidence that McAb7E10 preferen-
tially binds to the cell surface ATPase β subunit, and can
inhibit cell proliferation and induce apoptosis in MV4-11
and HL-60 AML cells. The effect of McAb7E10 on the
proliferation of MV4-11 and HL-60 cells was evaluated
using the MTT assay. Compared to control mouse IgG
treated cells, after 120 h, the relative inhibitory rates in
5, 10 and 50 ug/mL McAb7E10 treated MV4-11 cells
were 24.5%, 44% and 69.6%, respectively (Figure 3C).
After 120 h, the relative inhibitory rates in 5, 10 and 50
ug/mL McAb7E10 treated HL-60 cells were 39.4%, 62.1%
and 81.9%, respectively (Figure 3D). These results indi-
cate that McAb7E10 can significantly inhibit the pro-
liferation of AML cells in vitro.
Using cell cycle analysis and Annexin V staining, a
subpopulation of cells before the G1 population was
detected after treatment with McAb7E10, indicating
cells with abnormal nuclei which can be considered to
be apoptotic and dead cells. The relative rate of apop-
tosis in 5, 10 and 50 ug/mL McAb7E10 treated MV4-11
cells was 3.6 ± 0.83%, 8.4 ± 1.69% and 17.3 ± 2.56%
compared to 1.5% ± 0.85% in mouse IgG treated cells
(p < 0.01, Figure 4A, 4B). The relative rate of apoptosis
in 5, 10 and 50 ug/mL McAb7E10 treated HL-60 cells
was 5.5 ± 2.37%, 11.3 ± 3.62% and 19.9 ± 3.31% compared
to 1.56% ± 0.97% in mouse IgG treated cells (p < 0.01,
Figure 4A, 4C). To determine whether McAb7E10 canantibody with a high valency against F1F0 ATPase β subunit was
E10 antibody detected a single immunoreactive band in HUVEC
but did not detect recombinant human ATPase α subunit protein
evaluated using BIAcore. The affinity of McAb7E10 to the recombinant
nt was KDMcAb7E10 = 3.26E
–10.
Figure 3 McAb7E10 inhibits cell surface ATP generation and proliferation in AML cell. To examine the inhibitory effect of the antibody on
ATP synthesis, a cell surface ATP generation assay was performed. Results showed that McAb7E10 antibody significantly inhibited ATP synthesis in
AML cells. The effect of McAb7E10 on the proliferation of the AML cell lines MV4-11 and HL-60 was evaluated using the MTT assay. (A, B) ATP
generation on the surface of MV4-11 (A) and HL-60 (B) cells is inhibited dose-dependently in the presence of McAb7E10 and oligomycin.
Oligomycin, a known inhibitor of ATP synthase F1, was used as positive control and mouse IgG as negative control. Data represent means ± SD.
(C) Proliferation analysis of MV4-11 cells treated with mouse IgG and McAb7E10. At 120 h, the relative inhibitory rates for 5, 10 and 50 μg/mL
McAb7E10 treated MV4-11 cells were 24.5%, 44% and 69.6% respectively, compared to control mouse IgG treated cells. (D) Proliferation analysis
of HL-60 cells treated with mouse IgG and McAb7E10. At 120 h, the relative inhibitory rates for 5, 10 and 50 μg/mL McAb7E10 treated HL-60 cells
were 39.4%, 62.1% and 81.9% respectively, compared to control mouse IgG treated cells.
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of cells with Annexin V test Kit. The data showed that
the relative apotosis rate of 50ug/ml McAb7E10 treated
MV4-11 cells was 50.5% ± 7.04% vs mouse IgG treated
cells was 21.9% ± 3.11% P < 0.01 (Figure 5 A-C). The
relative apotosis rate of 50ug/ml McAb7E10 on HL-60
cells was 32.9% ± 4.52% vs mouse IgG treated cells
was15.3% ± 3.95% P < 0.01 (Figure 5D).
ATPase β subunit inhibition provides a target for
immuotherapy in hematologic malignancies
The cell surface ATPase β subunit acts as a high-density
lipoprotein (HDL) receptor, through binding of apolipo-
protein A-I in hepatocytes, and also regulates lipoprotein
internalization in endothelial cells [21]; however the
effects downstream of the cell surface ATPase β subunit
remain to be determined. ATPase β subunits have been
detected on the membrane of tumor cells, raising the
possibility that the structure of the β subunit protein on
the cell surface may perform a different function to the
inner mitochondrial protein structure. Our findings indi-
cate that ectopic expression of the ATPase β subunit is a
tumor-associated antigen in hematological malignancies.Although the function of the cell surface ATPase β sub-
unit requires further study, this study implies that the
ATPase β subunit plays an important role in cancer cell
proliferation and apoptosis. Our findings are in agree-
ment with previous studies which have indicated that
angiostatin, plasminogen kringle 1–5 (K1–5), McAb
against the ATPase β subunit [3,35] and small molecular
inhibitors [1,36] can bind to ATP synthase on the cell
surface and inhibit endothelial cell proliferation, migra-
tion, trigger apoptosis [3-6,10,14,19].
Cell surface ATP synthase is more active at a low
extracellular pH [21]; therefore, ectopic expression of
the ATPase β subunit may play an important role in the
survival of cells suffering an energy shortage or during
treatment with chemotherapy drugs, indicating cell sur-
face ATP synthase may play important role in the devel-
opment and treatment resistance of hematological
malignancies. Our study suggests that abnormal cell sur-
face expression of ecto-F1F0-ATPase β subunit may pro-
vide a potential target for cancer immunotherapy in
hematological malignancies.
F1F0 ATP synthase was recently reported to be a co-
chaperone of heat shock protein Hsp90, as F1F0 ATP
Figure 4 Analysis of effect of McAb7E10 on the cell cycle in AML cell lines. Cells were harvested, fixed, stained with propidium iodide
staining and analyzed by flow cytometry. (A) Cell cycle analysis results of MV4-11 and HL-60 cell treated with different dose of McAb7E10. (B) The
relative rate of apoptosis in 5, 10 and 50 ug/mL McAb7E10 treated MV4-11 cells was 3.6 ± 0.83%, 8.4 ± 1.69% and 17.3 ± 2.56% compared to 1.5%
± 0.85% in mouse IgG treated cells, p < 0.01. (C) The relative rate of apoptosis in 5, 10 and 50 ug/mL McAb7E10 treated HL-60 cells was 5.5 ±
2.37%, 11.3 ± 3.62% and 19.9 ± 3.31% compared to 1.56% ± 0.97% in mouse IgG treated cells, p < 0.01.
Figure 5 McAb7E10 induces apoptosis in AML cell lines. (A, B) Annexin V staining and flow cytometry was used to confirm that McAb7E10
induced apoptosis in AML cells. (C) The relative rate of apoptosis in 50 μg/ml McAb7E10 treated MV4-11 cells was 50.5% ± 7.04% vs 21.9% ±
3.11% in mouse IgG treated cells, p < 0.01. (D) The relative rate of apoptosis in 50 μg/ml McAb7E10 treated HL-60 cells was 32.9% ± 4.52% vs
15.3% ± 3.95% in mouse IgG treated cells, p < 0.01.
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client proteins in cell lysate from MCF-7, T47D, MDA-
MB-453 and HT-29 cancer cells [37]. Heat shock pro-
teins are often overexpressed in human malignancies,
including AML. Hsp90 is the major chaperone required
for stabilization of the multiple oncogenic kinases
involved in the development of AML [38]. Hsp90 client
proteins are also involved in the regulation of apoptosis,
proliferation, autophagy and cell cycle progression, and
several hsp90 client proteins are considered to be pos-
sible therapeutic targets for the treatment of AML [39].
Hsp90 inhibitors could be used as single agents or po-
tentially, in combination with other targeted treatments
such as a functional ATP synthase β subunit antibody.
This study indicates that clinical focus of hsp90 inhibi-
tors and F1F0-ATP β subunit synthase functional anti-
bodies should be directed towards hematological
malignancies, as well as solid tumors and malignant
melanoma.
Conclusions
This study demonstrates that the β subunit of F1F0
ATPase is expressed on the cell surface of several
leukemia cell lines with between 0.1% and 56% of cells
expressing the ecto-F1F0-ATPase β subunit. We pre-
pared a McAb against the ecto-F1F0-ATPase β subunit,
which significantly inhibited proliferation and induced
apoptosis in cell lines derived from AML in vitro. These
findings indicate that expression of the ecto-F1F0-
ATPase β subunit is a cancer-associated antigen in
hematological malignancies. The ecto-F1F0-ATPase β
subunit provides a potential target for immunotherapy
in AML and other hematological malignancies.
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